Cyclacel pharmaceuticals reports new clinical data from ongoing, phase 2 study of oral fadraciclib at the 2024 eortc-nci-aacr symposium

New clinical data from ongoing, phase 2 study of oral fadraciclib at the 2024 ena symposium. patients preselected for cdkn2a and/or cdkn2b abnormalities

NCI Ratings Summary

NCI Quant Ranking